Stay updated with breaking news from Hal Barron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer and Merck have each won FDA approvals in the past year for new pneumococcal vaccines, but GSK aims to top both of them with its $2.1 billion acquisition of Affinivax. That biotech’s Phase 3-ready vaccine candidate addresses more bacterial strains than any pneumococcal vaccines currently available.
The acquisition of the U.S.-based biotech bolsters GSK's vaccine roster.
Investegate announcements from GlaxoSmithKline PLC, Result of AGM
LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in financing. Among the investors is GlaxoSmithKline, which is teaming up with the biotech startup in a multi-target drug discovery alliance.
Jeff Bezos and Peter Thiel are pouring huge sums into startups aiming to keep us all young – or even cheat death. And the science isn’t as far-fetched as you might think